Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers†

Abstract

These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.